{{Rsnum
|rsid=9662388
|Gene=FMN2
|Chromosome=1
|position=240388923
|Orientation=plus
|GMAF=0.1538
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=FMN2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 3.6 | 16.2 | 80.2
| HCB | 0.0 | 11.9 | 88.1
| JPT | 0.0 | 7.1 | 92.9
| YRI | 18.5 | 48.6 | 32.9
| ASW | 12.3 | 43.9 | 43.9
| CHB | 0.0 | 11.9 | 88.1
| CHD | 0.9 | 14.8 | 84.3
| GIH | 0.0 | 25.0 | 75.0
| LWK | 20.0 | 50.9 | 29.1
| MEX | 0.0 | 14.0 | 86.0
| MKK | 13.5 | 42.3 | 44.2
| TSI | 3.0 | 16.8 | 80.2
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs9662388
|Name_s=
|Gene_s=FMN2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 176. Study population/ethnicity: 87 European descent Caucasians and 89 Yorubans. Significance metric(s): p = 0.000003. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109396
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9662388
|overall_frequency_n=20
|overall_frequency_d=128
|overall_frequency=0.15625
|n_genomes=17
|n_genomes_annotated=0
|n_haplomes=21
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | Illumina Human 1M}}